Not yet recruiting
Gastroenteropancreatic neuroendocrine tumour disease+5
Not yet recruitingStudy on the Safety and Effectiveness of Domvanalimab and Zimberelimab for Adults with Advanced Rare Cancers Resistant to Standard Treatment
Registered drugNo placebo
Study on the Safety and Effectiveness of Domvanalimab and Zimberelimab for Adults with Advanced Rare Cancers Resistant to Standard Treatment
Registered drugNo placebo
- Disease:Gastroenteropancreatic neuroendocrine tumour diseasePeritoneal mesothelioma malignant+4
- Substances:DomvanalimabFluorouracil+3
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Domvanalimab
- Sponsor:Hospices Civils De Lyon